May 26th 2021
In part 1 of this interview, Cate Lockhart, executive director of the Biologics and Biosimilar Collective Intelligence Consortium, details some of her expectations for further growth of the US biosimilar market.
April 3rd 2021
By Sarfaraz K. Niazi, PhD
Sarfaraz K. Niazi, PhD, a member of The Center for Biosimilars® Advisory Board, recounts a debate with a young clinician over the reliability of biosimilarity testing.
March 20th 2021
Kenneth Komorny, PharmD, BCPS, was a co-lead on development of National Comprehensive Cancer Network (NCCN) recommendations for biosimilar management. He explains some of the positions the NCCN has taken.
March 9th 2021
By Tony Hagen
Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of Biosimilars at Cardinal Health, discusses motivating factors that affect use of biosimilars in oncology.
March 6th 2021
Minnesota legislators introduce what could possibly become the first law to curtail payers' rights to determine which biologics patients have access to.
March 4th 2021
Investigators evaluated trial spending and reasons for biologics license application failures.
February 28th 2021
Anar Dossa, director of Pharmacy Services at Pacific Blue Cross, discusses the company's involvement with British Columbia's biosimilars switching program.
February 27th 2021
Biosimilars have come a long way, and their path has mirrored that of generics—fraught with obstacles. Still, a stronger embrace is needed from physicians and payers.
February 21st 2021
We sat down with Sarfaraz Niazi, PhD, an adjunct professor and biosimilar industry expert, to discuss the potential impact high-concentration adalimumab products could have on the US market.
February 15th 2021
Patient characteristics are predictive of whether a switch to a biosimilar is likely to be accepted, investigators found.
